SCHEMBL681833

SCHEMBL681833

CC(c1cc2ccccc2nc1Cl)n1nc(I)c2c(N)ncnc21

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 11/20 0.59
SRC P12931 11/20 0.59
PIK3CD O00329 11/20 0.59
ABL1 P00519 8/20 0.59
PIK3CA P42336 7/20 0.59
PIK3CB P42338 7/20 0.59
PRKDC P78527 7/20 0.59
KDR P35968 7/20 0.59
EGFR P00533 6/20 0.59
HCK P08631 6/20 0.59
MTOR P42345 6/20 0.59
EPHB4 P54760 6/20 0.59
PIK3C2B O00750 1/20 0.48
BACE1 P56817 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
RET P07949 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL685194 0.86 PIK3CG (0.72) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL681998 0.83 PIK3CG (0.70) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL15892706 0.82 PIK3CG (0.49) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL795195 0.78 PIK3CG (0.58) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL682010 0.75 PIK3CD (0.67) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL681085 0.74 PIK3CG (0.69) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL17331915 0.73 PIK3CG (0.47) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL17331933 0.72 PIK3CD (0.43) PIK3CGSRCPIK3CDABL1PIK3CA
SCHEMBL29749330 0.71 PIK3CD (0.60) PIK3CGPIK3CDPIK3CAPIK3CB
SCHEMBL26611415 0.71 PIK3CD (0.60) PIK3CGPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790228-B2 Heterocyclic kinase inhibitors INTELLIKINE LLC (US) 2017-10-17 US disclosed
US-9790228-B2 Heterocyclic kinase inhibitors INTELLIKINE LLC (US) 2017-10-17 US disclosed
US-20160168157-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE LLC 2016-06-16 US disclosed
US-20160168157-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE LLC 2016-06-16 US disclosed
US-9296742-B2 Heterocyclic kinase inhibitors INTELLIKINE LLC (US) 2016-03-29 US disclosed
US-9296742-B2 Heterocyclic kinase inhibitors INTELLIKINE LLC (US) 2016-03-29 US disclosed
US-20140206685-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE LLC (US) 2014-07-24 US disclosed
US-20140206685-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE LLC (US) 2014-07-24 US disclosed
US-20110281866-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE, INC. (US) 2011-11-17 US disclosed
US-20110281866-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE, INC. (US) 2011-11-17 US disclosed
WO-2010036380-A1 HETEROCYCLIC KINASE INHIBITORS INTELLIKINE, INC. (US) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168157-A1 HETEROCYCLIC KINASE INHIBITORS MAP3K13, MAP3K3, CDK3 PIK3CG 191/4885SRC 182/4885PIK3CD 147/4885
US-20140206685-A1 HETEROCYCLIC KINASE INHIBITORS MAP3K13, MAP3K3, CDK3 PIK3CG 191/4885SRC 182/4885PIK3CD 147/4885
US-20110281866-A1 HETEROCYCLIC KINASE INHIBITORS MAP3K13, MAP3K3, CDK3 PIK3CG 191/4885SRC 182/4885PIK3CD 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.